Primovist Regulatory Post Marketing Surveillance (PMS)

NCT00924248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4358

Last updated 2012-09-19

No results posted yet for this study

Summary

The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice

Conditions

  • Liver

Interventions

DRUG

Gadoxetic acid disodium (Primovist, BAY86-4873)

Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Completion
2011-05-31

Countries

  • South Korea

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00924248 on ClinicalTrials.gov